Malta - inglese - Medicines Authority

venus pharma gmbh am bahnhof 1-3, werne, d 59368, germany - concentrate for solution for infusion - docetaxel 20 mg/ml - antineoplastic agents

Malta - inglese - Medicines Authority

fresenius kabi limited - potassium iodide; copper chloride; zinc chloride; manganese chloride; sodium fluoride; sodium selenite - concentrate for solution for infusion - potassium iodide 1.31 µg/ml; copper chloride 53.7 µg/ml; zinc chloride 521 µg/ml; manganese chloride 3.6 µg/ml; sodium fluoride 126 µg/ml; sodium selenite 4.38 µg/ml - blood substitutes and perfusion solutions

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - zinc chloride; copper chloride 2h2o; manganese chloride 4h2o; sodium selenite anhydrous; sodium fluoride; potassium iodide - concentrate for solution for infusion - . percent volume/volume - electrolyte solutions; electrolytes in combination with other drugs

Regno Unito - inglese - myHealthbox

dr. reddy’s laboratories (uk) ltd - docetaxel - concentrate for solution for infusion (sterile concentrate) - 20mg/ml - taxanes - in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: • operable node-positive breast cancer • operable node-negative breast cancer.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - copper chloride dihydrate 53.7 µg/ml equivalent to 20 µg/0.315 µmol cu/ml; manganese chloride tetrahydrate 3.6 µg/ml (tetrahydrate, =1µg/18.2nmol mn/ml); potassium iodide 1.31 µg/ml equivalent to 1 µg/7.88 nmol i/ml; sodium fluoride 126 µg/ml equivalent to 57 µg/3.0 µmol f/ml; sodium selenite 4.38 µg/ml (anhydrous =2µg/25.3nmol se/ml); zinc chloride 521 µg/ml equivalent to 250 µg/3.82 µmol zn/ml - solution for infusion - active: copper chloride dihydrate 53.7 µg/ml equivalent to 20 µg/0.315 µmol cu/ml manganese chloride tetrahydrate 3.6 µg/ml (tetrahydrate, =1µg/18.2nmol mn/ml) potassium iodide 1.31 µg/ml equivalent to 1 µg/7.88 nmol i/ml sodium fluoride 126 µg/ml equivalent to 57 µg/3.0 µmol f/ml sodium selenite 4.38 µg/ml (anhydrous =2µg/25.3nmol se/ml) zinc chloride 521 µg/ml equivalent to 250 µg/3.82 µmol zn/ml excipient: hydrochloric acid water for injection - peditrace is indicated in premature and full-term infants and children needing intravenous nutrition to supply the basal requirements of trace elements.

Malta - inglese - Medicines Authority

fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - concentrate for solution for infusion - iodine 1.96 µg/ml selenium 7 µg/ml zinc 500 µg/ml copper 40 µg/ml magnesium 1 µg/ml - blood substitutes and perfusion solutions

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - copper chloride dihydrate; manganese chloride tetrahydrate; potassium iodide; sodium selenite anhydrous; zinc chloride - concentrate for solution for infusion - electrolytes in combination with other drugs

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for infusion - 20 mg/2ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol nitrogen polysorbate 80 - metastatic breast cancer docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for infusion - 80 mg/8ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol nitrogen polysorbate 80 - metastatic breast cancer docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - tirofiban hydrochloride monohydrate 0.281 mg/ml equivalent to 0.25 mg/ml tirofiban;   - concentrate for infusion - 0.25 mg/ml - active: tirofiban hydrochloride monohydrate 0.281 mg/ml equivalent to 0.25 mg/ml tirofiban   excipient: citric acid hydrochloric acid sodium chloride sodium citrate dihydrate sodium hydroxide water for injection